SARS-CoV-2 (2019-nCoV) Spike Neutralizing Antibody, Rabbit Mab

RRID Number: AB_2857936
EliteRmab®, manufactured by recombinant technology
1/3
Price:
Size:
Number:

SARS-CoV-2 (2019-nCoV) Spike Neutralizing Antibody, Rabbit Mab General Information

Product name
SARS-CoV-2 (2019-nCoV) Spike Neutralizing Antibody, Rabbit Mab
Validated applications
WB,ELISA,Neutralization
Application notes
(Antibody's applications have not been validated with corresponding viruses. Optimal concentrations/dilutions should be determined by the end user.)
Specificity
2019-nCoV Coronavirus spike
Has cross-reactivity in ELISA with
SARS-CoV-2 (2019-nCoV) Spike S1 Protein (Catalog#40591-V08B1)
No cross-reactivity in ELISA with
SARS-CoV Spike S1 Protein (Cat# 40150-V08B1)
MERS-CoV Spike S1 Protein (Cat# 40069-V08B1)
HCoV-HKU1 (isolate N1) Spike S1 Protein (Cat# 40021-V08H)
HCoV-HKU1 (isolate N5) Spike S1 Protein (Cat# 40602-V08H)
HCoV-NL63 Spike S1 Protein (Cat# 40600-V08H)
HCoV-229E Spike S1 Protein (Cat# 40601-V08H)
HCoV-OC43 Spike S1+S2 ECD Protein (Cat# 40607-V08B)
Immunogen
Recombinant SARS-CoV-2 (2019-nCoV) Spike RBD-mFc Protein (Catalog#40592-V05H)
Preparation
This product is a recombinant monoclonal antibody expressed from HEK293 cells.
Source
Monoclonal Rabbit IgG Clone #001
Purification
Protein A
Formulation
0.2 μm filtered solution in PBS
Conjugate
Unconjugated
Endotoxin
< 3 EU/mg
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.

SARS-CoV-2 (2019-nCoV) Spike Neutralizing Antibody, Rabbit Mab Validated Applications

Application Dilution
WB 1-5 μg/mL
ELISA 0.5-1 μg/mL
Notes
Microneutralizaiton (MN): The neutralization activity is Measured by microneutralization assay in vitro. The virus microneutralizaiton (MN) test was performed on 293T-ACE2 cells infected with SARS-CoV-2 (2019-nCoV) Spike Pseudovirus under treatment of serial dilutions of neutralizing antibody. The infection was neutralized by increasing concentrations of Anti-SARS-CoV-2 Neutralizing Antibody (Catalog# 40592-R001). Rate of inhibition was determined by comparing the Relative Light Unit (RLU) of Luciferase reporter in different antibody concentrations. The IC50 is typically 0.11 µg/mL.
Please Note: Optimal concentrations/dilutions should be determined by the end user.

SARS-CoV-2 (2019-nCoV) Spike Neutralizing Antibody, Rabbit Mab Images

Serial dilutions of Anti-SARS-CoV-2 Neutralizing Antibody (Catalog# 40592-R001) was detected by SARS-CoV-2 (2019-nCoV) Inhibitor Screening ELISA Kit (Catalog# KIT001). The IC50 is typically 0.59nM.
The neutralization activity is Measured by microneutralization assay in vitro. The virus microneutralizaiton (MN) test was performed on 293T-ACE2 cells infected with SARS-CoV-2 (2019-nCoV) Spike Pseudovirus under treatment of serial dilutions of neutralizing antibody. The infection was neutralized by increasing concentrations of Anti-SARS-CoV-2 Neutralizing Antibody (Catalog# 40592-R001). Rate of inhibition was determined by comparing the Relative Light Unit (RLU) of Luciferase reporter in different antibody concentrations. The IC50 is typically 0.11 µg/mL.

Anti-SARS-CoV-2 Spike rabbit monoclonal antibody in 1ug/ml.

Lane A:  SARS-CoV Spike/RBD Protein (40150-V08B2)(30ng)

Lane B: SARS-CoV-2 (2019-nCoV) Spike RBD-His Recombinant Protein (40592-V08B)(30ng)

Secondary

Goat Anti-Rabbit IgG (H+L)/HRP  at 1/10000 dilution.

Developed using the ECL technique.

Performed under reducing conditions.

SARS-CoV-2 (2019-nCoV) Spike Neutralizing Antibody, Rabbit Mab: Synonyms

Anti-coronavirus spike Antibody; Anti-cov spike Antibody; Anti-ncov RBD Antibody; Anti-ncov s1 Antibody; Anti-ncov s2 Antibody; Anti-ncov spike Antibody; Anti-NCP-CoV RBD Antibody; Anti-NCP-CoV s1 Antibody; Anti-NCP-CoV s2 Antibody; Anti-NCP-CoV Spike Antibody; Anti-novel coronavirus RBD Antibody; Anti-novel coronavirus s1 Antibody; Anti-novel coronavirus s2 Antibody; Anti-novel coronavirus spike Antibody; Anti-RBD Antibody; Anti-S1 Antibody; Anti-S2 Antibody; Anti-Spike RBD Antibody

Coronavirus spike Background Information

The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2; DPP4, dipeptidyl peptidase-4; APN, aminopeptidase N; CEACAM, carcinoembryonic antigen-related cell adhesion molecule 1; Sia, sialic acid; O-ac Sia, O-acetylated sialic acid. The spike is essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. It's been reported that SARS-CoV-2 (COVID-19 coronavirus, 2019-nCoV) can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. The main functions for the Spike protein are summarized as: Mediate receptor binding and membrane fusion; Defines the range of the hosts and specificity of the virus; Main component to bind with the neutralizing antibody; Key target for vaccine design; Can be transmitted between different hosts through gene recombination or mutation of the receptor binding domain (RBD), leading to a higher mortality rate.
References
  • Shen S, et al. (2007) Expression, glycosylation, and modification of the spike (S) glycoprotein of SARS CoV. Methods Mol Biol. 379: 127-35.
  • Du L, et al. (2009) The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 7 (3): 226-36.
  • Xiao X, et al. (2004) The SARS-CoV S glycoprotein. Cell Mol Life Sci. 61 (19-20): 2428-30.

Standard Antibody Development Service

Rabbit MAb

Mouse MAb

Rabbit PAb

Fast Antibody Development Service

Mouse MAb

Rabbit PAb

Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait U.S.A.